NextCure Inc
$ 13.04
1.40%
25 Feb - close price
- Market Cap 45,082,300 USD
- Current Price $ 13.04
- High / Low $ 13.62 / 12.69
- Stock P/E N/A
- Book Value 8.84
- EPS -23.81
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.58 %
- ROE -1.17 %
- 52 Week High 15.74
- 52 Week Low 2.69
About
NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.
Analyst Target Price
$17.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-07-31 | 2025-04-30 | 2025-03-19 | 2024-11-04 | 2024-08-01 | 2024-05-02 | 2024-03-21 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-03-02 |
| Reported EPS | -3.22 | -11.29 | -0.39 | -0.41 | -0.41 | -0.55 | -0.61 | -0.52 | -0.51 | -0.64 | -0.58 | -0.62 |
| Estimated EPS | -0.45 | -0.425 | -0.4 | -0.36 | -0.34 | -0.38 | -0.46 | -0.54 | -0.66 | -0.59 | -0.64 | -0.66 |
| Surprise | -2.77 | -10.865 | 0.01 | -0.05 | -0.07 | -0.17 | -0.15 | 0.02 | 0.15 | -0.05 | 0.06 | 0.04 |
| Surprise Percentage | -615.5556% | -2556.4706% | 2.5% | -13.8889% | -20.5882% | -44.7368% | -32.6087% | 3.7037% | 22.7273% | -8.4746% | 9.375% | 6.0606% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -2.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NXTC
2026-01-24 04:57:51
NextCure, Inc. announced updates on its antibody-drug conjugate (ADC) programs, SIM0505 and LNCB74, and reported its financial position. Data for SIM0505's Phase 1 dose escalation study is expected in Q2 2026, while LNCB74 has expanded into higher dose cohorts, with a trial progress update anticipated in H2 2026. The company also reported preliminary unaudited cash, cash equivalents, and marketable securities of approximately $41.8 million as of December 31, 2025, expected to fund operations into the first half of 2027.
2026-01-23 20:28:13
NextCure, Inc. (NASDAQ:NXTC) announced updates on its antibody-drug conjugate (ADC) programs: SIM0505 is expected to release Phase 1 dose escalation study data in Q2 2026, and LNCB74 has progressed to higher dose cohorts, with a trial progress update anticipated in H2 2026. The company reported preliminary unaudited cash of $41.8 million as of year-end 2025, expected to fund operations into the first half of 2027. Despite a recent surge in share price, NextCure is burning cash quickly, though it recently completed a $21.5 million private placement to extend its financial runway.
2026-01-23 20:28:13
NextCure, Inc. (Nasdaq: NXTC) provided updates on its two antibody drug conjugate (ADC) programs and its preliminary year-end 2025 cash position. The company anticipates Phase 1 dose escalation data for SIM0505 (CDH6 ADC) in Q2 2026 and expects to give a trial progress update for LNCB74 (B7-H4 ADC) in the second half of 2026 due to enrollment delays. NextCure also reported preliminary cash, cash equivalents, and marketable securities of approximately $41.8 million as of December 31, 2025, which it expects to fund operations into the first half of 2027.
2026-01-23 20:16:00
NextCure, Inc. provided updates on its two antibody drug conjugate (ADC) programs, SIM0505 and LNCB74, and reported its preliminary year-end 2025 cash position. The company anticipates presenting Phase 1 dose escalation data for SIM0505 in Q2 2026 and expects to provide a trial progress update for LNCB74 in the second half of 2026 due to enrollment delays. NextCure also stated that its financial resources of approximately $41.8 million are sufficient to fund operations into the first half of 2027.
2026-01-23 12:57:57
Next Cure Inc. (NXTC) announced progress in its antibody-drug conjugate (ADC) programs, SIM0505 and LNCB74, both targeting solid tumors. The company expects to present initial Phase 1 data for SIM0505 in Q2 2026, while LNCB74's dose escalation has advanced into higher cohorts with an updated trial progress report anticipated in H2 2026. Next Cure also reported a strong cash position of approximately $41.8 million, extending its cash runway into the first half of 2027.
2026-01-23 12:57:57
NextCure (NXTC) provided updates on its antibody-drug conjugate (ADC) candidates and financial standing. The company anticipates presenting Phase 1 dose-escalation data for SIM0505 in Q2 2026 and is advancing LNCB74 into higher-dose cohorts, with a trial progress update expected in the second half of 2026. With approximately $41.8 million in cash as of December 31, 2025, NextCure projects its operations to be funded into the first half of 2027.
